Potency analysis of cellular therapies: the emerging role of molecular assays

被引:27
|
作者
Stroncek, David F. [1 ]
Jin, Ping [1 ]
Wang, Ena [1 ]
Jett, Betsy [1 ]
机构
[1] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA
关键词
D O I
10.1186/1479-5876-5-24
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biological activity that is linked to a relevant biological property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such are flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of noncoding microRNA which play an important role in cellular development, differentiation, metabolism and signal transduction can distinguish different types of stem cells and leukocytes. Both gene and microRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and microRNA expression microarrays in potency testing of cellular therapies is discussed.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Role of Extracellular Matrix in Cardiac Cellular Therapies
    Hematti, Peiman
    CARDIAC EXTRACELLULAR MATRIX: FUNDAMENTAL SCIENCE TO CLINICAL APPLICATIONS, 2018, 1098 : 173 - 188
  • [42] Emerging molecular subtypes and therapies in acute lymphoblastic leukemia
    Davis, Katelynn
    Sheikh, Taimoor
    Aggarwal, Nidhi
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2023, 40 (03) : 202 - 215
  • [43] Emerging Molecular Therapies for the Treatment of Acute Lymphoblastic Leukemia
    Vasekar, Monali
    Allen, Joshua E.
    Joudeh, Jamal
    Claxton, David
    IMPACT OF GENETIC TARGETS ON CANCER THERAPY, 2013, 779 : 341 - 358
  • [44] Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
    Canale, Matteo
    Monti, Manlio
    Rapposelli, Ilario Giovanni
    Ulivi, Paola
    Sullo, Francesco Giulio
    Bartolini, Giulia
    Tiberi, Elisa
    Frassineti, Giovanni Luca
    CANCERS, 2021, 13 (22)
  • [45] Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
    Warren, Annabelle M.
    Knudsen, Soren T.
    Cooper, Mark E.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (07) : 579 - 591
  • [46] Melanoma: Molecular pathogenesis and emerging target therapies (Review)
    Russo, Alessia E.
    Torrisi, Elena
    Bevelacqua, Ylenia
    Perrotta, Rosario
    Libra, Massimo
    McCubrey, James A.
    Spandidos, Demetrios A.
    Stivala, Franca
    Malaponte, Grazia
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (06) : 1481 - 1489
  • [47] Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
    Smallridge, Robert C.
    Marlow, Laura A.
    Copland, John A.
    ENDOCRINE-RELATED CANCER, 2009, 16 (01) : 17 - 44
  • [48] Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer
    Liu, Jakub
    Mroczek, Magdalena
    Mach, Anna
    Stepien, Maria
    Aplas, Angelika
    Pronobis-Szczylik, Bartosz
    Bukowski, Szymon
    Mielczarek, Magda
    Gajewska, Ewelina
    Topolski, Piotr
    Krol, Zbigniew J.
    Szyda, Joanna
    Dobosz, Paula
    CANCERS, 2023, 15 (03)
  • [49] Ovarian cancer: emerging molecular-targeted therapies
    Sourbier, Carole
    BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 147 - 154
  • [50] Emerging insights into the molecular and cellular basis of glioblastoma
    Dunn, Gavin P.
    Rinne, Mikael L.
    Wykosky, Jill
    Genovese, Giannicola
    Quayle, Steven N.
    Dunn, Ian F.
    Agarwalla, Pankaj K.
    Chheda, Milan G.
    Campos, Benito
    Wang, Alan
    Brennan, Cameron
    Ligon, Keith L.
    Furnari, Frank
    Cavenee, Webster K.
    Depinho, Ronald A.
    Chin, Lynda
    Hahn, William C.
    GENES & DEVELOPMENT, 2012, 26 (08) : 756 - 784